Cargando…

The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis

BACKGROUND: An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. METHODS: A meta-analysis was performed to assess the correlation between le...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lilong, Yuan, Qihang, Li, Man, Chai, Dongqi, Deng, Wenhong, Wang, Weixing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708253/
https://www.ncbi.nlm.nih.gov/pubmed/33256658
http://dx.doi.org/10.1186/s12885-020-07651-1
_version_ 1783617526687596544
author Zhang, Lilong
Yuan, Qihang
Li, Man
Chai, Dongqi
Deng, Wenhong
Wang, Weixing
author_facet Zhang, Lilong
Yuan, Qihang
Li, Man
Chai, Dongqi
Deng, Wenhong
Wang, Weixing
author_sort Zhang, Lilong
collection PubMed
description BACKGROUND: An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. METHODS: A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. RESULTS: Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). CONCLUSION: The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis.
format Online
Article
Text
id pubmed-7708253
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77082532020-12-02 The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis Zhang, Lilong Yuan, Qihang Li, Man Chai, Dongqi Deng, Wenhong Wang, Weixing BMC Cancer Research Article BACKGROUND: An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. METHODS: A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. RESULTS: Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). CONCLUSION: The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis. BioMed Central 2020-11-30 /pmc/articles/PMC7708253/ /pubmed/33256658 http://dx.doi.org/10.1186/s12885-020-07651-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zhang, Lilong
Yuan, Qihang
Li, Man
Chai, Dongqi
Deng, Wenhong
Wang, Weixing
The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_full The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_fullStr The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_full_unstemmed The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_short The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
title_sort association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708253/
https://www.ncbi.nlm.nih.gov/pubmed/33256658
http://dx.doi.org/10.1186/s12885-020-07651-1
work_keys_str_mv AT zhanglilong theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT yuanqihang theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT liman theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT chaidongqi theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT dengwenhong theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT wangweixing theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT zhanglilong associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT yuanqihang associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT liman associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT chaidongqi associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT dengwenhong associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis
AT wangweixing associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis